Medtronic Infuse Bone Graft Lawsuits 2026: $22M Paid, Hundreds of Cases Dismissed in Ohio — Who Can Still File?
Some Infuse patients can still file claims in 2026, but recent rulings have narrowed the path. Medtronic paid $22 million to settle about 950 cases in 2014, and a federal judge in Ohio dismissed hundreds more in 2026. Whether you qualify turns on how the device was used in your surgery — and whether your state’s deadline is still open.
Key Facts
- Medtronic agreed to pay $22 million to resolve the claims of an estimated 950 claimants (2014), and reserved a $120–140 million special charge for roughly 3,800 additional filed and unfiled claims — all documented in company disclosures.
- The FDA approved Infuse in 2002 for one use only: single-level fusion in the L4–S1 region of the lumbar spine, performed through the front of the body and always with Medtronic’s LT-Cage device.
- As much as 80–85% of the Infuse Medtronic sold was used off-label — for unapproved spinal levels, approaches, and anatomies — according to widely cited MedPageToday estimates.
- More than 10,000 people have sued over Infuse since 2008 (Orthopedics This Week), while Medtronic says over one million patients have received the product.
- In 2026, U.S. District Judge Timothy S. Black dismissed hundreds of Infuse cases tied to one Ohio surgeon’s patients — and Medtronic separately agreed to a $43 million investor settlement, a securities case unrelated to patient injuries.
What Infuse Is — in One Paragraph
INFUSE Bone Graft is Medtronic’s tradename for rhBMP-2 — recombinant human bone morphogenetic protein-2, a laboratory-made protein that stimulates bone growth. In spinal fusion surgery, where vertebrae are permanently joined to stop back pain, Infuse was marketed as a modern alternative to harvesting bone from the patient’s own hip. The idea was elegant. The execution, according to thousands of lawsuits and a U.S. Senate investigation, was not.
The One Surgery the FDA Actually Approved It For
When the FDA granted Infuse its original approval in 2002, the authorization was surgically narrow: a single-level fusion between the L4 and S1 vertebrae of the lower spine, approached from the front of the body (anterior lumbar interbody fusion), and used together with Medtronic’s LT-Cage implant. Later approvals added open tibia fractures and certain oral and dental uses — and in December 2015, two more narrow indications. Everything else was off-label.
Off-label needs a plain definition: it means a doctor used the product in a way the FDA never approved — a different spinal level, a posterior approach through the back, multiple levels at once, or the neck and upper spine. Off-label use by a surgeon is legal and common across medicine. What a manufacturer may not do is promote those unapproved uses — and that alleged promotion sits at the center of the Infuse litigation, much as off-label marketing drove earlier device battles like the IVC filter lawsuits, where thousands of patients alleged injuries from retrievable filters left in place too long.
The Senate Report That Changed Everything
In 2012, the U.S. Senate Finance Committee concluded that Medtronic had deliberately omitted evidence of complications from the medical literature while aggressively promoting Infuse for off-label uses — paying surgeon-consultants millions and, investigators found, effectively ghost-writing favorable journal articles. An independent Yale University review of the trial data later highlighted adverse events the published literature had downplayed.
The injuries patients reported were severe: uncontrolled bone growth pressing on nerves and the spinal cord, nerve damage, chronic severe pain, urinary problems, difficulty breathing and swallowing when Infuse was used in the neck, and — in men — retrograde ejaculation causing sterility.
The $22 Million Settlement — and What It Didn’t Cover
In May 2014, Medtronic announced it would pay approximately $22 million to resolve the claims of an estimated 950 claimants — explicitly a compromise of disputed claims, with no admission of liability — while disclosing a $120–140 million special charge for an estimated 3,800 additional filed and unfiled claims its lawyers said were coming.
What the settlement did not do was end the litigation. Roughly 750 filed cases brought by about 1,200 plaintiffs remained pending across the country, most in early procedural stages — and new claims kept arriving for years. Individual recoveries were never publicly broken down, and compensation varies widely by case; most settlements are confidential. Anyone quoting you a guaranteed figure for an Infuse claim is selling, not advising.
The 2026 Ohio Dismissals: What They Mean for You
The most important recent development came from federal court in southern Ohio. U.S. District Judge Timothy S. Black dismissed hundreds of Infuse lawsuits brought by former patients of Cincinnati orthopedic surgeon Atiq Durrani — who fled to Pakistan after a 2013 indictment over his procedures — ruling the plaintiffs had failed to prove valid claims against Medtronic over the alleged off-label use.
Two lessons emerge. First, these dismissals were case-specific: they do not legally kill anyone else’s claim, and courts decide each plaintiff’s evidence on its own. Second, they reveal the bar you must clear — it is not enough to show Infuse was used off-label in your surgery. You must connect that specific use to your specific injury with medical evidence, and navigate the preemption defense (the argument that federal FDA approval blocks state lawsuits) that device makers deploy. The parallel to recent device litigation is instructive: courts dismissed only the weakest-documented tranches, as seen when judges culled cases in the Bair Hugger warming-blanket litigation, while well-evidenced claims marched on.
Who Can Still File in 2026
New claims remain possible, but the checklist is strict. One: Infuse was used in your spine surgery in a way the FDA never approved — no LT-Cage, a posterior approach, multiple levels, or cervical/thoracic placement. Your operative report will show this; get it. Two: you suffered a documented injury plausibly tied to the product — revision surgery, nerve damage, uncontrolled bone growth, or the complications listed above. Three: your state’s statute of limitations is still open — most states allow roughly two years from when you discovered, or should have discovered, that Infuse caused the harm, but the range varies and the clock may already be running.
A fourth factor matters more than most patients expect: who you sue. Claims against Medtronic face the preemption defense; claims against the surgeon sound in medical malpractice, with different deadlines and proof. Many patients pursue both. Start with paper, not phone calls: request your complete surgical records — the operative report naming the implanted products, implant logs, all post-operative imaging — write a dated timeline of symptoms, and sign nothing without independent legal advice. Then get a case evaluation from a firm that has litigated Infuse or similar device cases; most work on contingency. For clear, plain-language explainers of complicated health and money subjects, the Problem Solved channel on YouTube turns difficult topics into practical, watchable guides. Device makers settle cases they fear losing at trial — as the Exactech implant litigation showed, even billion-dollar corporate fights turn on individual medical evidence.
Who Benefits From This — and Who Does Not
Patients with off-label use and a documented injury. If Infuse was used in your spine surgery outside the approved use — no LT-Cage, a posterior approach, multiple levels, or cervical or thoracic placement — and you later suffered a documented injury such as revision surgery, nerve damage, or uncontrolled bone growth, you are the core reader of this guide: the first step is to request your operative report and check how the product was used.
Patients with a new, linking diagnosis. If you only later discovered that Infuse caused your current problems — for example through a new diagnosis connecting your symptoms to the implant — you may still fall within your state's deadline under the discovery rule: check the deadline in your state immediately rather than counting from the surgery date.
Patients weighing both legal theories. If you are considering a claim against the manufacturer as well as a possible claim against your surgeon — for instance over off-label use without proper informed consent — this guide helps you raise both theories at your first legal consultation, since malpractice deadlines are often shorter.
Who does not benefit. If you received Infuse exactly in its approved use — a single-level fusion between L4 and S1, from the front, with the LT-Cage — and suffered no injury, this guide offers no path. Nor do investors in the separate securities settlement benefit: none of that money goes to surgical patients. And without medical proof connecting the specific use to your specific injury, off-label use alone is not enough — as the 2026 Ohio dismissals show. For a related device case, see our guide to Bard PowerPort lawsuits.
Frequently Asked Questions
I had Infuse implanted in 2015 and now need revision surgery. Is it too late?
Maybe not. Many states start the filing clock when you discovered — or reasonably should have discovered — that Infuse caused your injury, not on the surgery date. A new diagnosis linking your current problems to the implant can reopen the window. Get legal advice immediately; do not assume.
Does the Ohio dismissal mean my Infuse case is dead?
No. Judge Black’s ruling covered specific plaintiffs and their specific evidence; it sets no binding rule for your case. It does signal, however, that courts demand tight proof connecting off-label use to injury — which is why your medical records matter more than any headline.
What was the $43 million Medtronic settlement I read about?
That was a securities case: institutional investors alleged Medtronic misled shareholders about Infuse’s risks between September 2010 and June 2011. It is entirely separate from patient injury claims — none of that money goes to surgical patients.
Can I sue my surgeon instead of Medtronic?
Possibly. If your surgeon used Infuse off-label without proper informed consent, or performed the surgery negligently, a medical-malpractice claim may exist alongside — or instead of — a product claim against Medtronic. Malpractice deadlines are often shorter, so raise both theories at your first legal consultation.
Who benefits from this guide, and how do I start?
The guide benefits most patients in whom Infuse was used outside its approved use and who suffered a documented injury, and patients with a new diagnosis linking their problems to the implant. Start here: request your complete operative report with the implant log, write a dated timeline of your symptoms, and have the deadline in your state checked — before signing anything, get a case evaluation from a firm that has litigated Infuse or similar device cases.
Who does not benefit — or who is not eligible?
Patients who received Infuse in its approved use and suffered no injury do not fall under these claims. Investors in the securities settlement receive no patient money. And anyone who cannot medically prove the link between the specific use and their own injury will have little prospect after the 2026 Ohio rulings — off-label use alone is not enough.
This article is general information only — not legal or medical advice. Surgical history and legal deadlines are individual matters; consult a qualified attorney in your state and discuss any medical concerns with your doctor.